|
|
 |
|
|
|
|
Factoid of the Day
|
Wednesday, July 16, 2025
|
|
The U.S. Food and Drug Administration (FDA) reported that it approved 16 new drugs in the first half of 2025 (1H'25), according to its own release. The total lags the 21 new drugs approved in 1H'24, as well as the 26 approved in 1H'23. The FDA approved a record 59 novel drugs over the 2018 calendar year. For comparative purposes, the FDA approved a total of 50 new drugs in 2024, down from 55 approvals in 2023.
|
|
First Trust Target Outcome ETFs®
|
| |
Unit Investment Trusts Upcoming Deposit Information |
Initial Offer Date |
| |
Click Here
for CUSIP Information.
|
| • |
Defensive Equity Buy-Write, 17 |
7/17/2025 |
| • |
Global Commodities Companies Buy-Write, 20 |
7/17/2025 |
| • |
Technology Dividend Buy-Write, 28 |
7/17/2025 |
| • |
Sabrient Baker's Dozen,3rd Qtr 2025 |
7/18/2025 |
| • |
Select DSIP, 3rd Qtr 2025 |
7/18/2025 |
| • |
Vest Large Cap Deep Buffered 20, 86 |
7/18/2025 |
| • |
Balanced Income Select, 150 |
7/22/2025 |
| • |
Preferred Income, 130 |
7/22/2025 |
| • |
Vest Large Cap Buffered 10, 83 |
7/22/2025 |
| • |
Equity Income Opportunity, 34 |
7/23/2025 |
| • |
Income Dividend Equity Allocation (IDEA), 46 |
7/23/2025 |
| • |
Mega-Cap, 78 |
7/23/2025 |
| • |
Municipal Income Opportunities Closed-End, 111 |
7/23/2025 |
| • |
Water Utility & Infrastructure Select, 79 |
7/23/2025 |
| • |
Balanced Income Equity and ETF, 75 |
7/24/2025 |
| • |
California Municipal Income Closed-End and ETF, 11 |
7/24/2025 |
| • |
Dividend Growers and Tax-Advantaged Income, 44 |
7/24/2025 |
| • |
Tactical Income, 86 |
7/24/2025 |
| • |
Vest Small Cap Buffered 20, 12 |
7/24/2025 |
| • |
Capital Strength, 75 |
7/25/2025 |
| • |
REIT Growth & Income Select, 73 |
7/25/2025 |
| • |
Vest Enhanced Large Cap Buffered 15, 29 |
7/28/2025 |
| • |
Vest Nasdaq 100 Buffered 10, 20 |
7/28/2025 |
| • |
Municipal Income ETF, 20 |
7/29/2025 |
| • |
Aerospace & Defense, 49 |
7/30/2025 |
| • |
American Heroes, 4 |
7/30/2025 |
| • |
High-Yield Income Closed-End, 120 |
7/30/2025 |
| • |
Richard Bernstein Advisors Tactical Series, American Industrial Renaissance®, 2025-3 |
7/30/2025 |
| • |
International Capital Strength, 68 |
7/31/2025 |
| • |
SMid Capital Strength, 68 |
7/31/2025 |
| • |
Election, 36 |
8/4/2025 |
| • |
Vest 2-Year Large Cap Buffered 20, 24 |
8/4/2025 |
| • |
American Agenda, 33 |
8/5/2025 |
| • |
Dividend Growth, 35 |
8/5/2025 |
| • |
Energy Select, 97 |
8/5/2025 |
| • |
Technology Select, 99 |
8/5/2025 |
| • |
Strategic Income Closed-End, 107 |
8/6/2025 |
| • |
Strategic Income Select Closed-End, 86 |
8/6/2025 |
| • |
Sabrient Dividend, 53 |
8/8/2025 |
| • |
Vest Large Cap Deep Buffered 30, 43 |
8/8/2025 |
| • |
Dow® Target 10, August 2025 |
8/11/2025 |
| • |
Market Strength Allocation Opportunity, 35 |
8/11/2025 |
| • |
SMid Earnings Leaders, 2 |
8/11/2025 |
| • |
High Dividend Equity Allocation, 56 |
8/13/2025 |
| • |
FT Diversified Target Income, 11 |
8/14/2025 |
| • |
Vest Nasdaq 100 Buffered 20, 25 |
8/14/2025 |
| • |
Dividend Strength Opportunity, 35 |
8/15/2025 |
| • |
Dividend Strength, 70 |
8/15/2025 |
| • |
Equity Income Select, 87 |
8/15/2025 |
| • |
Sabrient Forward Looking Value, 13 |
8/15/2025 |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|